Advertisement

Topics

Biogen Inc. Company Profile

11:03 EDT 23rd May 2018 | BioPortfolio

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.


News Articles [315 Associated News Articles listed on BioPortfolio]

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe Biogen Inc. (Nasdaq: BIIB) and ...

Biogen, Neurimmune Announce Option Exercise For Aducanumab

NewsBiogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 i...

Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies

WESTON (dpa-AFX) - Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced they have expanded strategic collaboration through a new ten-year collaboration agreement to develop antisense drug cand...

Biogen-Aktie: Fehlschlag sollte nicht von Erfolgschancen ablenken! - Aktienanalyse

New York - Biogen-Aktienanalyse von Analyst Michael Yee von Jefferies & Co: Aktienanalyst Michael Yee vom Investmenthaus Jefferies & Co empfiehlt die Aktien des US-Biotechkonzerns Biogen Inc. (ISIN...

Biogen to Acquire Phase 2-Ready Schizophenia Drug from Pfizer

Biogen is entering neuropsychiatry drug development with a deal to acquire a schizophrenia drug candidate from Pfizer. Cambridge, MA-based Biogen (NASDAQ: BIIB) is paying Pfizer $75 million up front f...

Biogen boosts pipeline with $1bn Ionis deal

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its $1 billion drug development deal with Ionis Pharmaceuticals. Perhaps signifying the ...

Biogen to buy Pfizer's neurology drug in deal nearing US$600 million

Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for cognitive impairment associated with schizophrenia in a deal whose value could near US$600 million. FILE PHOTO: A sig...

Biogen-Aktie: Potenzial wird unterschätzt!

Zürich - Biogen-Aktienanalyse von Analyst Carter Gould von der UBS: Laut einer Aktienanalyse empfiehlt der Analyst Carter Gould von der UBS die Aktien des US-Biotechkonzerns Biogen Inc. (ISIN US090.....

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.

Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion mole...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalentl...

Companies [31 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Inc.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hema...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

More Information about "Biogen Inc." on BioPortfolio

We have published hundreds of Biogen Inc. news stories on BioPortfolio along with dozens of Biogen Inc. Clinical Trials and PubMed Articles about Biogen Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Inc. Companies in our database. You can also find out about relevant Biogen Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...


Corporate Database Quicklinks



Searches Linking to this Company Record